Core Viewpoint - East China Pharmaceutical Co., Ltd. has entered into a strategic partnership with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. to obtain exclusive commercialization rights for the oral formulation VC005 in mainland China, addressing the urgent medication needs of over ten million patients with autoimmune diseases [2][3]. Group 1: Partnership Details - East China Pharmaceutical's subsidiary, East China Pharmaceutical (Hangzhou) Co., Ltd., will pay an upfront fee of 50 million yuan and up to 180 million yuan in milestone payments for the registration of VC005 [2]. - VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor designed to reduce inflammation and immune cell activation, currently in clinical development for various autoimmune diseases [2]. Group 2: Market Opportunity - The autoimmune disease treatment market presents significant unmet clinical needs due to the diverse types of autoimmune diseases and their complex mechanisms, coupled with a large patient base [2]. - The oral formulation of VC005 offers higher compliance, convenience, and accessibility compared to traditional injectable forms, making it particularly beneficial for patients requiring long-term treatment [3]. Group 3: Strategic Positioning - The autoimmune field is one of the three core therapeutic areas prioritized by East China Pharmaceutical, which has been actively enhancing its capabilities through the introduction of leading global technologies and products [3]. - The addition of VC005 is expected to enrich East China Pharmaceutical's portfolio in the dermatological oral formulation space, creating effective synergies with existing products and strengthening its core competitiveness in the autoimmune sector [3].

Group 1 - The core point of the news is that East China Pharmaceutical has entered into an exclusive commercialization agreement with Jiangsu Weikail for the oral formulation VC005, which is a novel and potent second-generation JAK1 inhibitor aimed at treating autoimmune diseases [1][3] - East China Pharmaceutical will pay an upfront fee of 50 million yuan and up to 180 million yuan in milestone payments for the commercialization rights of VC005 in mainland China [1] - VC005 is currently in phase III clinical trials for moderate to severe atopic dermatitis and has potential applications for other autoimmune diseases such as ankylosing spondylitis, rheumatoid arthritis, and vitiligo [1][2] Group 2 - Jiangsu Weikail, established in 2010, focuses on innovative drug development and has a pipeline that includes five clinical projects and several preclinical projects across various therapeutic areas including cardiovascular, oncology, and autoimmune diseases [2] - East China Pharmaceutical has identified autoimmune diseases as one of its three core therapeutic areas and has been actively enhancing its capabilities in this field, aiming to provide comprehensive treatment solutions for various autoimmune conditions [2][3] - The collaboration with Jiangsu Weikail is expected to enrich East China Pharmaceutical's portfolio in the oral formulation space for dermatological autoimmune diseases and align with its strategy of full coverage in the dermatology pipeline [3]

Core Viewpoint - Huadong Medicine has secured exclusive commercialization rights for the oral formulation VC005 in mainland China through a partnership with Jiangsu Weikail [1] Group 1: Company Overview - Huadong Medicine's subsidiary, Huadong Medicine Hangzhou, will make an initial payment of 50 million RMB and may pay up to 180 million RMB in milestone payments related to registration [1] - VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor aimed at treating inflammatory and autoimmune diseases, currently in Phase III clinical trials for moderate to severe atopic dermatitis [1]

Core Viewpoint - East China Pharmaceutical (华东医药) has entered into an exclusive commercialization agreement with Jiangsu Weikail (江苏威凯尔) for the oral formulation VC005, granting East China Pharmaceutical's subsidiary exclusive rights for commercialization in mainland China [1] Group 1 - East China Pharmaceutical's subsidiary, East China Pharmaceutical (Hangzhou) Co., Ltd., has officially signed the exclusive commercialization agreement on August 8 [1] - The agreement includes an initial payment of 50 million yuan and potential milestone payments up to 180 million yuan for registration [1]

Group 1 - East China Pharmaceutical's subsidiary has secured exclusive commercialization rights for VC005 oral formulation in mainland China, marking a significant addition to its autoimmune pipeline [1] - The strategic partnership involves an initial payment of 50 million RMB and potential milestone payments up to 180 million RMB [1] - VC005 is a novel, potent, and selective second-generation oral JAK1 inhibitor aimed at treating various autoimmune diseases, including moderate to severe atopic dermatitis, ankylosing spondylitis, rheumatoid arthritis, and vitiligo [2][4] Group 2 - The clinical development of VC005 has shown significant efficacy in moderate to severe atopic dermatitis, with a phase III trial currently underway [4] - The drug's mechanism selectively inhibits JAK1 while reducing JAK2 activity, potentially addressing safety concerns associated with excessive JAK2 inhibition [2] - The increasing prevalence of atopic dermatitis in China, with a recurrence rate of 75.9% over seven years, highlights the urgent need for effective treatments in this area [2] Group 3 - Traditional therapies for atopic dermatitis have limitations due to side effects and administration challenges, creating a demand for innovative, long-term management solutions [3] - The global prevalence of vitiligo is approximately 0.5%-2%, and its treatment remains challenging, further emphasizing the need for effective therapies like VC005 [3] - VC005's oral formulation offers higher compliance and convenience compared to traditional injectable therapies, making it a promising option for long-term treatment of autoimmune diseases [4] Group 4 - East China Pharmaceutical is strategically enhancing its autoimmune portfolio, focusing on innovative technologies and products to strengthen its market position [5][6] - The company has a comprehensive pipeline covering various autoimmune conditions, including skin, rheumatology, cardiovascular, and respiratory diseases [6] - The recent approval of its biosimilar product for psoriasis treatment and ongoing clinical trials for other indications demonstrate the company's commitment to expanding its therapeutic offerings [6][7]

格隆汇8月11日丨华东医药(000963.SZ)公布，2025年08月08日，华东医药股份有限公司全资子公司华东 医药(杭州)有限公司(简称"华东医药杭州")与江苏威凯尔医药科技股份有限公司(简称"江苏威凯尔")就 VC005达成的独家商业化合作协议正式生效。华东医药杭州获得江苏威凯尔的VC005口服剂型(简称"许 可产品"或"标的产品")于中国大陆的独家商业化许可权利。华东医药杭州将向江苏威凯尔支付5,000万元 人民币首付款，以及最高不超过1.8亿元人民币的注册里程碑付款。 ...

人民财讯8月11日电，华东医药（000963）8月11日晚间公告，8月8日，公司全资子公司华东医药(杭州) 有限公司(简称"华东医药杭州")与江苏威凯尔医药科技股份有限公司(简称"江苏威凯尔")就VC005达成的 独家商业化合作协议正式生效。华东医药杭州获得江苏威凯尔的VC005口服剂型于中国大陆的独家商业 化许可权利。华东医药杭州将向江苏威凯尔支付5000万元首付款，以及最高不超过1.8亿元的注册里程 碑付款。 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-078 华东医药股份有限公司 关于全资子公司签署产品独家商业化合作协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概况 2025 年 08 月 08 日，华东医药股份有限公司（以下简称 "本公 司"或"公司"）全资子公司华东医药（杭州）有限公司（以下简称"华 东医药杭州"）与江苏威凯尔医药科技股份有限公司（以下简称"江苏 威凯尔"）就 VC005 达成的独家商业化合作协议正式生效。华东医药 杭州获得江苏威凯尔的 VC005 口服剂型（以下简称"许可产品"或"标 的产品"）于中国大陆（以下简称"许可区域"）的独家商业化许可权利。 华东医药杭州将向江苏威凯尔支付 5,000 万元人民币首付款，以及最 高不超过 1.8 亿元人民币的注册里程碑付款。 本次交易按照公司投资审批程序进行了评审和决策。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。根据深交所《股票上市规则》的规定， 本次交易的决策权限在公司董事会授权范围内，无需提交公司股东会 审议。 ...

Core Viewpoint - East China Pharmaceutical announced an exclusive commercialization agreement with Jiangsu Weikail, acquiring exclusive commercialization rights for the oral formulation VC005 in mainland China [1] Group 1: Agreement Details - East China Pharmaceutical's subsidiary, East China Pharmaceutical Hangzhou, will pay an upfront fee of 50 million RMB and up to 180 million RMB in milestone payments for registration [1] - VC005 is a novel, potent, and highly selective second-generation oral JAK1 inhibitor, currently in Phase III clinical trials for moderate to severe atopic dermatitis [1]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the acceleration of PD-(L)1/VEGF and PD-(L)1/IL-2 dual antibodies, confirming the trend of upgrading single antibodies to multi-target therapies [5][14] - As of August 8, 2025, there are 32 PD-(L)1 tri-antibodies in clinical and preclinical stages globally, with 16 being PD-(L)1/VEGF tri-antibodies [5][14] - The report emphasizes the potential of PD-1/VEGF/IL-2 tri-target combination therapies to exhibit superior synergistic treatment effects [30][39] Summary by Sections Section 1: PD-(L)1 Dual Antibody Upgrades - The report notes the upgrade of PD-(L)1 dual antibodies, with 6 PD-(L)1/VEGF tri-antibodies entering clinical trials [5][14] - Multiple PD-(L)1/VEGF tri-antibodies show superior preclinical efficacy compared to competitors [6][16] - The PD-1/VEGF/IL-2 tri-target combination is expected to demonstrate enhanced synergistic treatment effects [30][39] Section 2: Market Performance - In the second week of August, the pharmaceutical and biotechnology sector declined by 0.84%, underperforming the CSI 300 index by 2.07 percentage points [41][46] - The medical consumables sector showed the largest increase, while the medical research outsourcing sector experienced the largest decline [46][47] Section 3: Recommended and Benefiting Companies - Recommended companies in pharmaceuticals and bioproducts include: Heng Rui Medicine, East China Pharmaceutical, Sanofi, and others [8] - CXO companies include WuXi AppTec, Tigermed, and others [8] - Companies in medical devices include Mindray Medical, United Imaging, and others [8]